Nelson's pediatric antimicrobial therapy

著者

• Bradley, John S. (John Sterling)
• Nelson, John D.
• Barnett, Elizabeth D.

書誌事項

Nelson's pediatric antimicrobial therapy

John S. Bradley, editor-in-chief ; John D. Nelson, emeritus ; Elizabeth D. Barnett, ... [et al.], contributing editors

American Academy of Pediatrics, c2022

28th ed

• 2022

注記

Includes bibliographical references (p. 309-334) and index

内容説明・目次

内容説明

Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. TOPICS INCLUDE Antimicrobial Therapy by Clinical Syndromes Antimicrobial Therapy for Neonates Choosing Among Antibiotics Antifungal Agents Antiviral Agents Antiparasitic Agents Oral Step-down Therapy for Serious Infections Prevention of Symptomatic Infection Approach to Antibiotic Allergies Antibiotic Stewardship New in the 28th Edition Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021-2022 Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase-producing enteric bacilli, if susceptible Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children New dosing for posaconazole suspension formulation New approaches to mucormycosis Added baloxavir for children 12+ years old

目次

Introduction Notable Changes to 2022 Nelson's Pediatric Antimicrobial Therapy, 28th Edition 1. Antimicrobial Therapy According to Clinical Syndromes A. Skin and Soft Tissue Infections B. Skeletal Infections C. Eye Infections D. Ear and Sinus Infections E. Oropharyngeal Infections F. Lower Respiratory Tract Infections G. Cardiovascular Infections H. Gastrointestinal Infections I. Genital and Sexually Transmitted Infections J. Central Nervous System Infections K. Urinary Tract Infections L. Miscellaneous Systemic Infections 2. Antimicrobial Therapy for Neonates A. Recommended Therapy for Selected Neonatal Conditions B. Antimicrobial Dosages for Neonates C. Aminoglycosides D. Vancomycin E. Use of Antimicrobials During Pregnancy or Breastfeeding 3. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens A. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Positive) B. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Negative) C. Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Anaerobes) D. Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens 4. Choosing Among Antibiotics Within a Class: Beta-lactams and Beta-lactamase Inhibitors, Macrolides, Aminoglycosides, and Fluoroquinolones 5. Preferred Therapy for Specific Fungal Pathogens A. Overview of More Common Fungal Pathogens and Their Usual Pattern of Antifungal SusceptibilitiesB. Systemic Infections C. Localized Mucocutaneous Infections 6. Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins 7. Preferred Therapy for Specific Viral Pathogens A. Overview of Non-HIV, Non-hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals B. Overview of Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals C. Preferred Therapy for Specific Viral Pathogens 8. Choosing Among Antiviral Agents 9. Preferred Therapy for Specific Parasitic Pathogens A. Selected Common Pathogenic Parasites and Suggested Agents for Treatment. B. Preferred Therapy for Specific Parasitic Pathogens 10. Choosing Among Antiparasitic Agents: Antimalarial Drugs, Nitroimidazoles, Benzimidazoles, and Neglected Tropical Diseases 11. How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes 12. Approach to Antibiotic Therapy of Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus 13. Antibiotic Therapy for Children Who Are Obese 14. Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections 15. Antimicrobial Prophylaxis/Prevention of Symptomatic Infection A. Postexposure Antimicrobial Prophylaxis to Prevent Infection B. Long-term Antimicrobial Prophylaxis to Prevent Symptomatic New Infection C. Prophylaxis of Symptomatic Disease in Children Who Have Asymptomatic Infection/Latent Infection D. Surgical/Procedure Prophylaxis 16. Approach to Antibiotic Allergies 17. Antibiotic Stewardship 18. Systemic and Topical Antimicrobial Dosing and Dose Forms A. Systemic Antimicrobials With Dosage Forms and Usual Dosages B. Topical Antimicrobials (Skin, Eye, Ear, Mucosa) Appendix: Nomogram for Determining Body Surface Area References Index

「Nielsen BookData」 より

詳細情報

• NII書誌ID(NCID): BC13998062
• ISBN:
  • 9781610025645
• 出版国コード: us
• タイトル言語コード: eng
• 本文言語コード: eng
• 出版地: Itasca
• ページ数/冊数: xiv, 366 p.
• 大きさ: 18 cm
• 分類:
  • DC23 : 618.9290461
• 件名:
  • LCSH : Communicable diseases in children -- Chemotherapy
  • LCSH : Antibacterial agents -- Therapeutic use